Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 4 351 M
EBIT 2017 1 130 M
Net income 2017 668 M
Debt 2017 4 621 M
Yield 2017 1,53%
Sales 2018 4 583 M
EBIT 2018 1 227 M
Net income 2018 744 M
Debt 2018 3 591 M
Yield 2018 1,73%
P/E ratio 2017 25,54
P/E ratio 2018 23,08
EV / Sales2017 4,65x
EV / Sales2018 4,19x
Capitalization 15 607 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
04/26 ORASURE TECHNOLOGIES : Grifols Strengthens Position as Global Provider of Diagno..
04/08 Spanish stock market rises 0.35%, closes at 10,361 points
04/06 ARADIGM : Announces Fourth Quarter 2016 and Full Year Financial Results
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/22 GRIFOLS : Global Blood Product Market 2017 - Grifols, Octapharma, BPL
03/21 Spanish stocks gain 0.77 %
03/13 GRIFOLS : edges closer to zero waste
03/01 HOLOGIC : Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth o..
01/31 GRIFOLS : closes the acquisition of Hologic's share of NAT donor screening unit ..
01/27 TERUMO : Global Medical Blood Transfusion Industry 2017 Market Solutions & Life-..
More news
Sector news : Biopharmaceuticals
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
04/27DJASTRAZENECA : Profit Drops on Decline in Blockbuster-Drug Revenue -- Update
04/27DJASTRAZENECA : Correction to AstraZeneca Profit Drops on Decline in Blockbuster-D..
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 23,1 €
Spread / Average Target -6,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Director
Víctor Grifols Roura Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%16 951
BIOGEN INC5.83%58 665
CSL LIMITED29.58%44 471
ALEXION PHARMACEUTICAL..3.73%28 574
GRIFOLS SA30.88%16 951
BIOMARIN PHARMACEUTICA..16.20%16 687
More Results